DOCSLIB.ORG

CYP7A1 Genotypes and Haplotypes Associated with Hypertension in an Obese Han Chinese Population

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CYP7A1 Genotypes and Haplotypes Associated with Hypertension in an Obese Han Chinese Population Hypertension Research (2011) 34, 722–727 & 2011 The Japanese Society of Hypertension All rights reserved 0916-9636/11 $32.00 www.nature.com/hr ORIGINAL ARTICLE CYP7A1 genotypes and haplotypes associated with hypertension in an obese Han Chinese population Lingyu Fu1,3, Yanyan Zhao2, Xiaomei Wu1, Hong Liu2, Jingpu Shi1,3, Jingyu Lu2 and Bo Zhou1 This study investigated the association between single-nucleotide polymorphisms (SNPs; rs3808607 and rs1125226) within the CYP7A1 promoter and hypertension susceptibility in a Han Chinese population. From 2003 through 2006, a population- based case–control study was performed in a cohort of 1187 randomly selected Han Chinese subjects. A sib-pair study for a transmission disequilibrium test analysis was carried out in 76 hypertensive (HT) families (n¼312) from northeastern Liaoning province. SNPs were detected using real-time PCR. No significant differences were found in the genotype or allele frequencies of either SNP (P40.05), with no excessive allele sharing. For rs3808607, the frequency of the AA genotype in obese hypertensive patients was 31.91%, significantly higher than in normotensive (NT) subjects (12.73%; odds ratio (OR)¼3.21, 95% confidence interval (CI)¼1.35–7.66). For rs3808607, the AA genotype frequency was significantly higher in obese male HT subjects (27.87%) than in matched NTs (7.41%; OR¼4.83, 95% CI¼1.03–22.65). After adjustment for environmental risk factors in obese participants, the AA genotype was associated with hypertension (OR¼3.395, 95% CI¼1.412–8.162). Among subjects with body mass index X28 kg mÀ2, the HT and NT groups had significantly different frequencies of Hap I (C/C) and Hap IV (A/A). The frequencies of rs3808607 alleles in the CYP7A1 gene differed significantly between obese HT and NT men. Haplotypes I and IV were associated with hypertension in obese participants. Hypertension Research (2011) 34, 722–727; doi:10.1038/hr.2011.18; published online 24 February 2011 Keywords: association; body mass index; cholesterol 7-hydroxylase promoter; haplotype; single-nucleotide polymorphism. INTRODUCTION which is a cytochrome P-450 enzyme. In the study by Toshio et al.,5 The population of northeastern China has an age-standardized the expression of CYP7A1 mRNA was decreased in spontaneously HT prevalence of hypertension of almost 35%, which has made it an hyperlipidemic rats. Furthermore, in our study population, intake of ideal region for the study of this disease.1 Several genetic cohort animal oil and blood lipid metabolism disorders were independent studies have been performed in this population, and associations have risk factors for hypertension, according to the preliminary results of been reported between the likelihood of developing hypertension and this study. Therefore, we selected CYP7A1 as a candidate gene for single-nucleotide polymorphisms (SNPs) within CYP4F2 (À421G/C)2 hypertension in our study population. and NOS2 (À1026C/A).3 Hypertension mostly arises as a complex The CYP7A1 gene spans approximately 10 kb and contains six quantitative trait that is affected by varying combinations of genetic exons, five introns, one 5¢-untranslated region and one 3¢-untranslated and environmental factors; the role of each gene is relatively minor, region, and maps onto chromosome 8q11.6 Several studies have so many additional studies on susceptibility genes are required. been performed to assess the association of CYP7A1 with diseases Hypertension rarely occurs in the absence of other metabolic related to lipid metabolism. Most studies concerning genetic varia- disturbances. Dyslipidemia is one of the earliest and most frequent tions in the CYP7A1 gene have focused on an A-C SNP in the metabolic disturbances in hypertensive (HT) individuals, occurring promoter region, which is at position À278 from the translation concomitantly in over one-third of patients with hypertension. The initiation codon or position À204 from the transcriptional start site. liver has a central role in the regulation and maintenance of whole- The results appear to be conflicting as to whether this polymorphism body sterol balance. Conversion of cholesterol into bile acids in the is significantly associated with, for example, plasma lipid levels,7–9 risk liver, together with the secretion of cholesterol into bile, is the major of arteriosclerosis10 and gallstone disease 11–13 in adults and children quantitative pathway for eliminating cholesterol from the body.4 The from Caucasian and Asian populations. Some intervention trials have initial stage of this process is catalyzed by the rate-limiting enzyme in suggested that the polymorphism has an important role in the the catabolism of cholesterol, cholesterol 7-hydroxylase (CYP7A1),4 metabolism of lipids.14,15 1Department of Clinical Epidemiology, The First Affiliated Hospital, China Medical University, Shenyang, China and 2Department of Medical Genetics, China Medical University, Shenyang, China 3These authors contributed equally to this work Correspondence: Professor J Shi and Professor L Fu, Department of Clinical Epidemiology, The First Affiliated Hospital, China Medical University, No. 155, Nan Jing Bei Street, Shenyang, Liaoning Province 110001, China. E-mail: [email protected] or [email protected] Received 11 October 2010; revised 26 December 2010; accepted 27 December 2010; published online 24 February 2011 CYP7A1 is associated with hypertension in obesity LFuet al 723 The HapMap linkage disequilibrium patterns and haplotype are listed in Table 1. Subgroups were divided according to their body structure can serve as a reference to select haplotype tagging mass index (BMI):17 low body weight, BMI o18.5 kg mÀ2;normal SNPs (htSNPs) for association studies. Various degrees of linkage body weight, BMI 18.5–23.9 kg mÀ2; overweight, BMI 24.0– disequilibrium exist across different regions in different populations. 27.9 kg mÀ2;obese,BMIX28 kg mÀ2. Ethical approval and informed As inferred from public HapMap data and analyzed by Nakamoto consent were obtained from the local ethics committee and from all et al.,16 rs3808607 (CYP7A1 À204C/A) and rs1125226 (CYP7A1 subjects prior to their inclusion into the study. À6791C/A) are likely to be the relevant htSNPs in the Han Chinese population in Beijing, China (CHB). Genotyping of CYP7A1 Therefore, rs3808607 and rs1125226 were selected in this study as DNA was isolated from whole blood with the use of FlexiGene DNA Kits tag variants to assess the genotypes of an extensive population in our (QIAgen, Hilden, Germany). The patients and the controls were genotyped for study. To the best of our knowledge, no studies, including the genome- the rs3808607 and rs1125226 variants by a TaqMan Assay with a 7500 HT Real- wide association studies, have investigated whether these two poly- Time PCR System (Applied Biosystems, Foster City, CA, USA); all of the morphisms are associated with the risk of hypertension. We aimed to reagents and synthesized probes were purchased from Applied Biosystems identify hypertension risk haplotypes of the CYP7A1 regulatory region (C_8893122_10 and C_27492121_20). Real-time PCR was performed using and estimate their impact on gene transcription, as well as their 12.5 mlTaqMan2Â universal master mix, 0.625 ml primer probe, 10.875 ml interaction with environmental factors. DNase-free water and 1 ml DNA sample, for a total volume of 25 ml per single reaction in a 96-well plate. In each assay run, DNase-free water was used as a non-template control, and DNA of a known genotype was used as a positive METHODS control. Assay conditions were 2 min at 501C, 10 min at 951C, 40 cycles of 921C Subjects for 15 s and 601C for 1 min. The post-assay analysis was performed using SDS From 2003 through 2006, a population-based case–control study was software (Applied Biosystems). The samples of genotyped CC, AA and CA were performed with 1187 subjects of Han Chinese origin, who were selected randomly and confirmed by sequencing (3100 Genetic Analyzer, selected by random sampling in the northeastern region of Liaoning Applied Biosystems). province, China. Additionally, a family-based study was conducted, consisting of 76 families with 312 members; each family had at least Statistical analyses two offspring and one parent with hypertension. For all the indivi- Data were analyzed by SPSS, version 13.0, for Windows (SPSS, Chicago, IL, duals, blood pressure (BP) was measured three separate times on the USA). The Hardy–Weinberg equilibrium was assessed with the use of w2-tests. right arm of seated subjects, with at least a 5-min rest between The differences in clinical characteristics between HTs and normotensives (NTs) measurements; the individual average was calculated from these were assessed by a two-sample t-test for quantitative variables and a w2-test for three measurements. Hypertension was defined as an average systolic categorical variables. Allele and genotype frequencies between the HT and BP X140 mm Hg and/or an average diastolic BP X90 mm Hg; sub- normotensive (NT) groups were compared using the w2-test. Multivariate jects with diabetes mellitus, renal disease or secondary hypertension, logistic regression analyses were used to assess the relationship between each as diagnosed by medical specialists, were excluded from the study. polymorphism and hypertension while considering the effects of other predictor Normotension was defined as BPo140/90 mm Hg with no history of variables. The probability for stepwise entry was 0.05 and the probability for stepwise removal was 0.1. ORs and 95% confidence
Load more

Recommended publications
  • Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid
    Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 231 _____________________________ _____________________________ Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid Cloning, Expression and Catalytic Properties of CYP4F8 and CYP4F21 BY JOHAN BYLUND ACTA UNIVERSITATIS UPSALIENSIS UPPSALA 2000 Dissertation for the Degree of Doctor of Philosophy (Faculty of Pharmacy) in Pharmaceutical Pharmacology presented at Uppsala University in 2000 ABSTRACT Bylund, J. 2000. Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid: Cloning, Expression and Catalytic Properties of CYP4F8 and CYP4F21. Acta Universitatis Upsaliensis. Comprehensive Summaries of Uppsala Dissertations from Faculty of Pharmacy 231 50 pp. Uppsala. ISBN 91-554-4784-8. Cytochrome P450 (P450 or CYP) is an enzyme system involved in the oxygenation of a wide range of endogenous compounds as well as foreign chemicals and drugs. This thesis describes investigations of P450-catalyzed oxygenation of prostaglandins, linoleic and arachidonic acids. The formation of bisallylic hydroxy metabolites of linoleic and arachidonic acids was studied with human recombinant P450s and with human liver microsomes. Several P450 enzymes catalyzed the formation of bisallylic hydroxy metabolites. Inhibition studies and stereochemical analysis of metabolites suggest that the enzyme CYP1A2 may contribute to the biosynthesis of bisallylic hydroxy fatty acid metabolites in adult human liver microsomes. 19R-Hydroxy-PGE and 20-hydroxy-PGE are major components of human and ovine semen, respectively. They are formed in the seminal vesicles, but the mechanism of their biosynthesis is unknown. Reverse transcription-polymerase chain reaction using degenerate primers for mammalian CYP4 family genes, revealed expression of two novel P450 genes in human and ovine seminal vesicles.
    [Show full text]
  • Synonymous Single Nucleotide Polymorphisms in Human Cytochrome
    DMD Fast Forward. Published on February 9, 2009 as doi:10.1124/dmd.108.026047 DMD #26047 TITLE PAGE: A BIOINFORMATICS APPROACH FOR THE PHENOTYPE PREDICTION OF NON- SYNONYMOUS SINGLE NUCLEOTIDE POLYMORPHISMS IN HUMAN CYTOCHROME P450S LIN-LIN WANG, YONG LI, SHU-FENG ZHOU Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing 100191, P. R. China (LL Wang & Y Li) Discipline of Chinese Medicine, School of Health Sciences, RMIT University, Bundoora, Victoria 3083, Australia (LL Wang & SF Zhou). 1 Copyright 2009 by the American Society for Pharmacology and Experimental Therapeutics. DMD #26047 RUNNING TITLE PAGE: a) Running title: Prediction of phenotype of human CYPs. b) Author for correspondence: A/Prof. Shu-Feng Zhou, MD, PhD Discipline of Chinese Medicine, School of Health Sciences, RMIT University, WHO Collaborating Center for Traditional Medicine, Bundoora, Victoria 3083, Australia. Tel: + 61 3 9925 7794; fax: +61 3 9925 7178. Email: [email protected] c) Number of text pages: 21 Number of tables: 10 Number of figures: 2 Number of references: 40 Number of words in Abstract: 249 Number of words in Introduction: 749 Number of words in Discussion: 1459 d) Non-standard abbreviations: CYP, cytochrome P450; nsSNP, non-synonymous single nucleotide polymorphism. 2 DMD #26047 ABSTRACT Non-synonymous single nucleotide polymorphisms (nsSNPs) in coding regions that can lead to amino acid changes may cause alteration of protein function and account for susceptivity to disease. Identification of deleterious nsSNPs from tolerant nsSNPs is important for characterizing the genetic basis of human disease, assessing individual susceptibility to disease, understanding the pathogenesis of disease, identifying molecular targets for drug treatment and conducting individualized pharmacotherapy.
    [Show full text]
  • Warfarin Sensitivity (CYP2C8, CYP2C9
    Patient Report |FINAL Section 79-1 of New York State Civil Rights Law requires informed consent be obtained from patients (or their legal guardians) prior to pursuing genetic testing. These forms must be kept on file by the ordering physician. Consent forms for genetic testing are available at www.aruplab.com. Incidental findings are not reported unless clinically significant but are available upon request. A Neg result indicates that no variants were detected. All variant alleles are defined based on consensus nomenclature and suggest reduced function of the associated protein(s). CYP2C8 and CYP2C9 are associated with inactivation of warfarin through metabolism. Variant alleles suggest reduced rates of warfarin metabolism, a prolonged time required to achieve steady-state concentrations, and a reduced dose requirement. CYP4F2 is associated with vitamin K recycling. Variant alleles suggest an increased dose requirement. VKORC1 is the therapeutic target for warfarin. Variant alleles suggest increased warfarin sensitivity and a reduced dose requirement. Dosing calculators such as that available through www.WarfarinDosing.org are available to predict loading and therapeutic/maintenance doses. This result has been reviewed and approved by , Ph.D. BACKGROUND INFORMATION: Warfarin Sensitivity (CYP2C8, CYP2C9 , CYP4F2, VKORC1) Genotyping CHARACTERISTICS: Warfarin sensitivity can lead to a life-threatening overdose event such as excessive bleeding. Genetic variation is recognized to explain a large proportion of variability in warfarin dose requirements. This test may predict individual warfarin sensitivity and non-standard dose requirements. The cytochrome P450 (CYP) isozymes 2C8 and 2C9 are involved in the metabolism of many drugs. Variants in the genes that code for CYP2C8 and CYP2C9 may influence pharmacokinetics of substrates such as warfarin, and may predict or explain non-standard dose requirements, therapeutic failure or adverse reactions.
    [Show full text]
  • Supplementary Tables, Figures and Other Documents
    Clinical Relevance of a 16-Gene Pharmacogenetic Panel Test for Medication Management in a Cohort of 135 Patients David Niedrig1,2, Ali Rahmany1,3, Kai Heib4, Karl-Dietrich Hatz4, Katja Ludin5, Andrea M. Burden3, Markus Béchir6, Andreas Serra7, Stefan Russmann1,3,7,* 1 drugsafety.ch; Zurich, Switzerland 2 Hospital Pharmacy, Clinic Hirslanden Zurich; Zurich Switzerland 3 Swiss Federal Institute of Technology Zurich (ETHZ); Zurich, Switzerland 4 INTLAB AG; Uetikon am See, Switzerland 5 Labor Risch, Molecular Genetics; Berne, Switzerland 6 Center for Internal Medicine, Clinic Hirslanden Aarau; Aarau, Switzerland 7 Institute of Internal Medicine and Nephrology, Clinic Hirslanden Zurich; Zurich, Switzerland * Correspondence: [email protected]; Tel.: +41 (0)44 221 1003 Supplementary Tables, Figures and Other Documents Figure S1: Example of credit-card sized pharmacogenomic profile issued to patients 1 Table S2: SNPs analyzed by the 16-gene panel test Gene Allele rs number ABCB1 Haplotypes 1236-2677- rs1045642 ABCB1 3435 rs1128503 ABCB1 rs2032582 COMT Haplotypes 6269-4633- rs4633 COMT 4818-4680 rs4680 COMT rs4818 COMT rs6269 CYP1A2 *1C rs2069514 CYP1A2 *1F rs762551 CYP1A2 *1K rs12720461 CYP1A2 *7 rs56107638 CYP1A2 *11 rs72547513 CYP2B6 *6 rs3745274 CYP2B6 *18 rs28399499 CYP2C19 *2 rs4244285 CYP2C19 *3 rs4986893 CYP2C19 *4 rs28399504 CYP2C19 *5 rs56337013 CYP2C19 *6 rs72552267 CYP2C19 *7 rs72558186 CYP2C19 *8 rs41291556 CYP2C19 *17 rs12248560 CYP2C9 *2 rs1799853 CYP2C9 *3 rs1057910 CYP2C9 *4 rs56165452 CYP2C9 *5 rs28371686 CYP2C9 *6 rs9332131 CYP2C9
    [Show full text]
  • Clinical Implications of 20-Hydroxyeicosatetraenoic Acid in the Kidney, Liver, Lung and Brain
    1 Review 2 Clinical Implications of 20-Hydroxyeicosatetraenoic 3 Acid in the Kidney, Liver, Lung and Brain: An 4 Emerging Therapeutic Target 5 Osama H. Elshenawy 1, Sherif M. Shoieb 1, Anwar Mohamed 1,2 and Ayman O.S. El-Kadi 1,* 6 1 Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton T6G 2E1, AB, Canada; 7 [email protected] (O.H.E.); [email protected] (S.M.S.); [email protected] (A.M.) 8 2 Department of Basic Medical Sciences, College of Medicine, Mohammed Bin Rashid University of 9 Medicine and Health Sciences, Dubai, United Arab Emirates 10 * Correspondence: [email protected]; Tel.: 780-492-3071; Fax: 780-492-1217 11 Academic Editor: Kishor M. Wasan 12 Received: 12 January 2017; Accepted: 15 February 2017; Published: 20 February 2017 13 Abstract: Cytochrome P450-mediated metabolism of arachidonic acid (AA) is an important 14 pathway for the formation of eicosanoids. The ω-hydroxylation of AA generates significant levels 15 of 20-hydroxyeicosatetraenoic acid (20-HETE) in various tissues. In the current review, we discussed 16 the role of 20-HETE in the kidney, liver, lung, and brain during physiological and 17 pathophysiological states. Moreover, we discussed the role of 20-HETE in tumor formation, 18 metabolic syndrome and diabetes. In the kidney, 20-HETE is involved in modulation of 19 preglomerular vascular tone and tubular ion transport. Furthermore, 20-HETE is involved in renal 20 ischemia/reperfusion (I/R) injury and polycystic kidney diseases. The role of 20-HETE in the liver is 21 not clearly understood although it represents 50%–75% of liver CYP-dependent AA metabolism, 22 and it is associated with liver cirrhotic ascites.
    [Show full text]
  • Effect of Genetic Variability in the CYP4F2, CYP4F11 and CYP4F12 Genes on Liver Mrna Levels and Warfarin Response
    Effect of genetic variability in the CYP4F2, CYP4F11 and CYP4F12 genes on liver mRNA levels and warfarin response J. Eunice Zhang1, Kathrin Klein2, Andrea L. Jorgensen3, Ben Francis3, Ana Alfirevic1, Stephane Bourgeois4, Panagiotis Deloukas4,5,6, Ulrich M. Zanger2 and Munir Pirmohamed1* 1Wolfson Centre for Personalized Medicine, Department of Molecular & Clinical Pharmacology, The University of Liverpool, UK 2Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tuebingen, Tuebingen, Germany. 3Department of Biostatistics, The University of Liverpool, UK 4William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK 5Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK. 6Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary Disorders, King Abdulaziz University, Jeddah, Saudi Arabia. Correspondence: Professor Sir Munir Pirmohamed Wolfson Centre for Personalised Medicine Department of Molecular & Clinical Pharmacology Block A: Waterhouse Buildings The University of Liverpool 1-5 Brownlow Street L69 3GL, UK [email protected] Running Title: Genotype-phenotype assessment of CYP4F12-CYP4F2-CYP4F11 region Keywords: warfarin, pharmacogenetics, mRNA expression, CYP4F2, CYP4F11, CYP4F12 1 Abstract Genetic polymorphisms in the gene encoding cytochrome P450 (CYP) 4F2, a vitamin K oxidase, affect stable warfarin dose requirements and time to therapeutic INR. CYP4F2 is part of the CYP4F gene cluster, which is highly polymorphic and exhibits a high degree of linkage disequilibrium, making it difficult to define causal variants. Our objective was to examine the effect of genetic variability in the CYP4F gene cluster on expression of the individual CYP4F genes and warfarin response. mRNA levels of the CYP4F gene cluster were quantified in human liver samples (n=149) obtained from a well characterized liver bank and fine mapping of the CYP4F gene cluster encompassing CYP4F2, CYP4F11 and CYP4F12 was performed.
    [Show full text]
  • Screening 20-Hete Inhibitors in Microsomal Incubates
    SCREENING 20-HETE INHIBITORS IN MICROSOMAL INCUBATES USING UPLC-MS/MS by Chenxiao Tang Bachelor of Science, Capital Medical University, 2014 Submitted to the Graduate Faculty of School of Pharmacy in partial fulfillment of the requirements for the degree of Master of Science University of Pittsburgh 2016 Copyright © by Chenxiao Tang 2016 ii SCREENING 20-HETE INHIBITORS IN MICROSOMAL INCUBATES USING UPLC-MS/MS Chenxiao Tang, B.S. University of Pittsburgh, 2016 20-hydroxyeicosatetraenoic acid (20-HETE) is a metabolite of arachidonic acid (AA) formed by cytochrome P450 (CYP) 4A11 and CYP4F2 in humans, with potent microvascular constriction activity. Inhibition of 20-HETE formation is neuroprotective in subarachnoid hemorrhage, cardiac arrest and thromboembolic stroke preclinical models. These findings suggest that inhibition of 20-HETE formation is a potential therapeutic strategy for neuroprotection after brain injury. At this point, a clinically relevant 20-HETE inhibitor is not available to be evaluated as a therapeutic intervention. Our goal is to identify a selective, metabolically stable, and potent 20-HETE inhibitor. Test compounds were obtained either via virtual screening against a CYP4F2 homology model or from scaffold hopping from structures of known inhibitors. Four different types of microsomes including human liver microsome (HLM), recombinant CYP4F2 (rCYP4F2), rat liver microsome (RLM) and rat kidney microsome (RKM) were used. AA was incubated in microsomes with/without compound for 20 min. 20-HETE formation rate was quantified using a validated UPLC-MS/MS assay and normalized by vehicle control group. Other eicosanoids including 15-, 12-HETEs, epoxyeicosatrienoic acids (EETs), iii and dihydroxyeicosatrienoic acids (DiHETs) were monitored simultaneously.
    [Show full text]
  • Biodiversity of P-450 Monooxygenase: Cross-Talk
    Cytochrome P450: Oxygen activation and biodiversty 1 Biodiversity of P-450 monooxygenase: Cross-talk between chemistry and biology Heme Fe(II)-CO complex 450 nm, different from those of hemoglobin and other heme proteins 410-420 nm. Cytochrome Pigment of 450 nm Cytochrome P450 CYP3A4…. 2 High Energy: Ultraviolet (UV) Low Energy: Infrared (IR) Soret band 420 nm or g-band Mb Fe(II) ---------- Mb Fe(II) + CO - - - - - - - Visible region Visible bands Q bands a-band, b-band b a 3 H2O/OH- O2 CO Fe(III) Fe(II) Fe(II) Fe(II) Soret band at 420 nm His His His His metHb deoxy Hb Oxy Hb Carbon monoxy Hb metMb deoxy Mb Oxy Mb Carbon monoxy Mb H2O/Substrate O2-Substrate CO Substrate Soret band at 450 nm Fe(III) Fe(II) Fe(II) Fe(II) Cytochrome P450 Cys Cys Cys Cys Active form 4 Monooxygenase Reactions by Cytochromes P450 (CYP) + + RH + O2 + NADPH + H → ROH + H2O + NADP RH: Hydrophobic (lipophilic) compounds, organic compounds, insoluble in water ROH: Less hydrophobic and slightly soluble in water. Drug metabolism in liver ROH + GST → R-GS GST: glutathione S-transferase ROH + UGT → R-UG UGT: glucuronosyltransferaseGlucuronic acid Insoluble compounds are converted into highly hydrophilic (water soluble) compounds. 5 Drug metabolism at liver: Sleeping pill, pain killer (Narcotic), carcinogen etc. Synthesis of steroid hormones (steroidgenesis) at adrenal cortex, brain, kidney, intestine, lung, Animal (Mammalian, Fish, Bird, Insect), Plants, Fungi, Bacteria 6 NSAID: non-steroid anti-inflammatory drug 7 8 9 10 11 Cytochrome P450: Cysteine-S binding to Fe(II) heme is important for activation of O2.
    [Show full text]
  • Pharmacogenomic Associations Tables
    Pharmacogenomic Associations Tables Disclaimer: This is educational material intended for health care professionals. This list is not comprehensive for all of the drugs in the pharmacopeia but focuses on commonly used drugs with high levels of evidence that the CYPs (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4 and CYP3A5 only) and other select genes are relevant to a given drug’s metabolism. If a drug is not listed, there is not enough evidence for inclusion at this time. Other CYPs and other genes not described here may also be relevant but are out of scope for this document. This educational material is not intended to supersede the care provider’s experience and knowledge of her or his patient to establish a diagnosis or a treatment plan. All medications require careful clinical monitoring regardless of the information presented here. Table of Contents Table 1: Substrates of Cytochrome P450 (CYP) Enzymes Table 2: Inhibitors of Cytochrome P450 (CYP) Enzymes Table 3: Inducers of Cytochrome P450 (CYP) Enzymes Table 4: Alternate drugs NOT metabolized by CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4 or CYP3A5 enzymes Table 5: Glucose-6-Phosphate Dehydrogenase (G6PD) Associated Drugs and Compounds Table 6: Additional Pharmacogenomic Genes & Associated Drugs Table 1: Substrates of Cytochrome P450 (CYP) Enzymes Allergy Labetalol CYP2C19 Immunosuppressives Loratadine CYP3A4 Lidocaine CYP1A2 CYP2D6 Cyclosporine CYP3A4/5 Analgesic/Anesthesiology CYP3A4/5 Sirolimus CYP3A4/5 Losartan CYP2C9 CYP3A4/5 Codeine CYP2D6 activates Tacrolimus CYP3A4/5 Lovastatin
    [Show full text]
  • Differential Expression of Prostaglandin I2 Synthase Associated with Arachidonic Acid Pathway in the Oral Squamous Cell Carcinoma
    Hindawi Journal of Oncology Volume 2018, Article ID 6301980, 13 pages https://doi.org/10.1155/2018/6301980 Research Article Differential Expression of Prostaglandin I2 Synthase Associated with Arachidonic Acid Pathway in the Oral Squamous Cell Carcinoma Anelise Russo ,1 Patr-cia M. Biselli-Chicote ,1 Rosa S. Kawasaki-Oyama,1 Márcia M. U. Castanhole-Nunes,1 José V. Maniglia,2 Dal-sio de Santi Neto,3 Érika C. Pavarino ,1 and Eny M. Goloni-Bertollo 1 1 Department of Molecular Biology: Biological and Genetics and Molecular Biology Research Unit – UPGEM, Sao˜ Jose´ do Rio Preto Medical School – FAMERP, Sao˜ Jose´ do Rio Preto, SP 15090-000, Brazil 2Department of Otorhinolaryngology and Head and Neck Surgery, FAMERP, Sao˜ Jose´ do Rio Preto, SP 15090-000, Brazil 3Department of Pathology, FAMERP, Sao˜ Jose´ do Rio Preto, SP 15090-000, Brazil Correspondence should be addressed to Anelise Russo; [email protected] and Eny M. Goloni-Bertollo; [email protected] Received 17 July 2018; Accepted 16 October 2018; Published 8 November 2018 Academic Editor: Tomas R. Chauncey Copyright © 2018 Anelise Russo et al. Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Introduction. Diferential expression of genes encoding cytochrome P450 (CYP) and other oxygenases enzymes involved in biotransformation mechanisms of endogenous and exogenous compounds can lead to oral tumor development. Objective.We aimed to identify the expression profle of these genes, searching for susceptibility biomarkers in oral squamous cell carcinoma.
    [Show full text]
  • The Role of Vitamin E Hydroxylases in Vitamin E Metabolism And
    THE ROLE OF VITAMIN E HYDROXYLASES IN VITAMIN E METABOLISM AND STATUS A Dissertation Presented to the Faculty of the Graduate School of Cornell University in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy by Sabrina Anne Bardowell August 2012 ©2012 Sabrina Anne Bardowell THE ROLE OF VITAMIN E HYDROXYLASES IN VITAMIN E METABOLISM AND STATUS Sabrina Anne Bardowell, Ph.D. Cornell University 2012 Vitamin E is a group of compounds that are considered to be the most important lipophilic antioxidants, however there is still much unknown about the biological actions of the various forms of vitamin E as well as the mechanisms that influence the concentration of vitamin E forms in tissues. Despite the common predominance of mainly γ-tocopherol (γ-TOH) in the diet, α-TOH is present in serum and tissues at levels 5-6 times that of γ-TOH. The biological rational for this selectivity remains an enigma. The focus of this work was on the selective post- absorptive catabolism of non-α-TOH forms via the vitamin E-ω-oxidation pathway. Cytochrome P450 4F2 (CYP4F2) is the only known human enzyme shown to display TOH-ω-hydroxylase activity. In an effort to investigate the role of TOH-ω-hydroxylase activity in vitamin E metabolism and status, the functional murine ortholog of CYP4F2 was identified and the consequences of its deletion on vitamin E metabolism and status were determined. In vivo and in vitro studies revealed Cyp4f14 to be the major, but not the only, vitamin E-ω-hydroxylase in mice, and to have critical function in regulating body-wide vitamin E status.
    [Show full text]
  • CYP2C9 and VKORC1 Testing for Warfarin Response
    Lab Management Guidelines v2.0.2019 CYP2C9, VKORC1, and CYP4F2 Testing for Warfarin Response MOL.TS.156.A v2.0.2019 Procedures addressed The inclusion of any procedure code in this table does not imply that the code is under management or requires prior authorization. Refer to the specific Health Plan's procedure code list for management requirements. Procedures addressed by this Procedure codes guideline CYP2C9 Genotyping 81227 VKORC1 Genotyping 81355 CYP4F2 Genotyping 81479 Warfarin responsiveness testing by G9143 genetic technique using any method What is Warfarin sensitivity testing? Definition Warfarin (Coumadin® ) is a commonly prescribed anticoagulant with a narrow therapeutic range and a 20-fold inter-individual variation in dose requirements.1 Incorrect dosage, especially during the initial dosing phase, is associated with either severe bleeding or failure to prevent thromboembolism.2 Approximately 21% of patients who receive anticoagulant therapy will experience a major or minor bleeding event.2 Environmental and genetic factors combined influence 55% of warfarin dose variability and include: age, height, body mass index (BMI), gender, diet, genetic variations in CYP2C9 and VKORC1, use of concomitant medications and indication for warfarin.3,4 The activity of two genes [cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit-1 (VKORC1)] impact the rate of warfarin metabolism and account for up to 40% of the inter-individual dose requirements for warfarin.4 The addition of a third gene, cytochrome P450 4F2 (CYP4F2) accounts for an additional 2% of warfarin dosing variability.5 CYP2C9 is a p450 enzyme that influences warfarin pharmacokinetics by impacting the rate of metabolism.
    [Show full text]